RPE65 and retinitis pigmentosa 1: At present, Luxturna (voretigene neparvovec) is the only approved gene therapy for RP, and it is only authorized for the treatment of a small sub-population of patients who have the RPE65 gene mutation, which represents 0.3–1% of all RP cases.